Primary non-alcoholic fatty liver disease in hypertensive patients
Luminita Latea, Stefania Negrea, Sorana Bolboaca
“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

Background
Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease affecting 15–25% of the general population.

Aims
The aim of this study was to investigate the prevalence of NAFLD and the relationship between insulin sensitivity and NAFLD in grade III high and very high cardiovascular risk essential hypertensive patients according to the circadian blood pressure (BP) rhythm.

Method
This four-year prospective study was conducted at the Department of Internal Medicine at Cluj-Napoca’s Diagnosis and Treatment Centre in Romania. The study included grade III essential hypertensive patients. Hypertensive patients were divided into four groups according to the diurnal index (DI) from ABPM monitoring: dipper (D), non-dipper (ND), reverse-dipper (RD), and extreme-dipper (ED). All hypertensive patients underwent 24 ABPM, blood tests and abdominal ultrasonography for the diagnosis of fatty liver disease.

Results
Thirty-five hypertensive patients were included in the study, with 31.42% ND, 11.43% RD, 8.57% ED and 48.57% D. The prevalence of NAFLD was significantly higher in ND, RD and ED when compared to D. When compared to the dipper group of hypertensive patients a statistically significantly higher level of plasma insulin was observed: in non-dipper [86.3±17.9 pmol/l vs. 62.2±20.3 pmol/l, p<0.05], in reverse dipper [88.3±18.6 pmol/l vs. 62.2±20.3 pmol/l] and in extreme-dippers [86.7±16.8 pmol/l vs. 62.2±20.3 pmol/l, p<0.05].

Conclusion
The altered dipping status (ND, RD, ED) of hypertension associated with a higher insulin resistance could be the pathogenetic link between the NAFLD and altered blood pressure status. Altered BP status could be a marker of NAFLD in hypertensive patients.

Key Words
Essential hypertension, primary non-alcoholic fatty liver disease, NAFLD, circadian blood pressure rhythm, insulin resistance

What this study adds:
1. Little is know about this subject
2. The altered dipping status of hypertension associated with a higher insulin resistance could be the pathogenetic link between the NAFLD and altered blood pressure status.
3. Altered BP status could be a marker of NAFLD in hypertensive patients.

Background
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum starting from fatty liver, fatty liver and inflammation to evidence of damage to hepatocytes and can progress to cirrhosis or in the most extreme form of NAFLD can progress to hepatocellular carcinoma or liver failure. Non-alcoholic fatty liver disease is considered the most common liver disease affecting 15–25% of the general population. Primary NAFLD results from insulin resistance and NAFLD is considered as part of the metabolic syndrome. Essential hypertension is considered an insulin resistant state and through the basis of insulin resistance mechanisms, recent studies consider NAFLD as an early mediator of atherosclerosis and an increased cardiovascular risk factor.

The aim of the present study was to investigate the prevalence of NAFLD in grade III high and very high...
cardiovascular additional risk hypertensive patients according to circadian BP rhythm and to investigate the relationship between insulin sensitivity and NAFLD in essential hypertensive patients according to the circadian BP rhythm.

**Method**

**Study population**

From November 2005 to December 2009 a prospective study was conducted. The study included consecutive eligible adult hypertensive patients admitted to the Department of Internal Medicine at Cluj-Napoca’s Diagnosis and Treatment Centre.

The study included patients of either sex with grade III essential hypertension and additional high and very high global cardiovascular risk. Essential hypertension was defined according to the ESC/ESH 2007 guidelines for the Management of Arterial Hypertension of European Society of Cardiology Guidelines Committee as office sitting systolic BP [SBP] of ≥180 mmHg and/or office diastolic BP [DBP] ≥110mmHg measured by mercury sphygmomanometer, at rest in a sitting position in at least three separate casual measurements within the last month.

Patients with mild or moderate essential hypertension or suspected secondary hypertension were excluded. Also patients with chronic alcoholism, diabetic mellitus, evidence of cardiovascular, pulmonary, renal, hepatic disease, and patients with previous drug-induced fatty liver treatment (corticoids, chronic salicylates, tricyclic antidepressants, tamoxifen, tetracyclines, synthetic oestrogens and amiodarone) were excluded from the study.

Thirty-five hypertensive patients gave their informed consent before taking part in the study, completed the inclusion criteria and were therefore enrolled in the study.

All hypertensive patients underwent 24-hour ambulatory BP monitoring (ABPM) [for systolic and diastolic BP evaluation], blood tests and abdominal ultrasonography.

The ABPM was performed with ABPM-04, 99/BP411 - Medibase. Before the beginning of ABPM, BP was measured with a mercury sphygmomanometer, with the patient seated for at least 10 minutes. The arm with higher BP values at sphygmomanometer evaluation was chosen for ABPM. In order to reduce errors during the day all patients were asked to ensure that the arm was always parallel to the trunk when the cuff was inflated. Readings were obtained automatically at 15 minute intervals from 7:00 am to 22:00 pm and 30-minute intervals from 22:00 pm to 7:00 am. All the measurements were performed by the same investigator, using the same equipment, both at the beginning of the study and during the follow-up.

Hypertensive patients were divided into four groups according to the diurnal index (DI) from ABPM monitoring: dipper (D), non-dipper (ND), reverse-dipper (RD), and extreme-dipper (ED). The diurnal index = 100 X (the average of the diurnal values – the average of the night values)/the average of the diurnal values (N >10%). Dipper patients were defined as 10%≤DI<20%, non-dipper defined as 0 ≤DI<10%, extreme-dipper defined as DI≥20%, reverse-dipper defined as DI<0.15.

The diagnosis of fatty liver, was established using the non-invasive method of abdominal ultrasound followed by the exclusion of the secondary causes of hepatic steatosis: a history of another known liver disease, alcohol intake of 30g/day or more for males and 20g/day or more for females, a positive serology for hepatitis B or C virus or ingestion of drugs known to produce hepatic steatosis. The liver ultrasonography scanning was performed by standard criteria by the same investigator, in all patients in the morning, after overnight fasting, using the same equipment (ESAOTE My Lab, with a 3.5-MHz transducer). The presence of liver steatosis was graded semi-quantitatively according to a previously reported scale: 0 - absent, 1 - mild, 2 - moderate and 3 - severe steatosis.

In all hypertensive patients who fasted overnight for biochemical and metabolic profile, blood samples were evaluated by standardised routine laboratory techniques.

Serum triglycerides, total, and HDL cholesterol, glucose, insulin, alanine amino transferase (ALT), aspartate amino-transferase (AST), gamma-glutamyl transferase (GGT) levels were measured, using routine automated assay methods. Reference range of values, are 0–40 IU/l for ALT, 0–37 IU/l for AST, 6–20 µIU/ml for insulinaemia, 0–50 IU/l for cGT, 70–170 mg/dl for triglycerides, 60–110 mg/dl for glucose, and up to 200 mg/dl for total cholesterol.

Insulin resistance was calculated by the homeostasis monitoring assessment (HOMA) formula. The HOMA index was calculated as the product of the fasting plasma insulin level (µU/mL) and the fasting plasma glucose level (mmol/L), divided by 22.5. Inverse relationship between insulin sensitivity and NAFLD in essential hypertensive patients according to the circadian BP rhythm.

**Statistical analysis**

Descriptive statistics, including means, SD, ranges and percentages, were used to characterise the study subjects. Statistical significance between groups was assessed by a Student’s t test in normally distributed for independent
samples. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 17 and the Statistica 8 program.

**Results**

NAFLD was present in 14 hypertensive patients (40%) with grade III essential hypertension with high and very high additional cardiovascular risk as reported in Figure 1.

**Figure 1: The prevalence of NAFLD in hypertensive patients**

![Image of Figure 1](image)

According to diurnal index from ABPM the 35 hypertensive patients were divided into four groups as follows: 48.57% (n=17) patients as dippers, 31.42% (n=11) patients as non-dipper, 11.43% (n=4) patients as reverse-dippers and 8.57% (n=3) patients as extreme-dippers.

No statistically significant differences were observed between the four groups of patients in terms of demographic baseline characteristics (p>0.05).

Baseline demographic, clinical and laboratory characteristics of the study population are presented in Table 1.

The prevalence of NAFLD was significantly higher in the non-dipper hypertensive patients group 54.54% (n=6), the reverse-dipper hypertensive patients group 50% (n=2) and the extreme-dipper hypertensive patients group 33.33% (n=1) compared to the dipper hypertensive patients group 29.41% (n=5) (p<0.05) as reported in Figure 2.

**Figure 2: The prevalence of NAFLD in hypertensive patients**

![Image of Figure 2](image)

The prevalence of liver steatosis grades according to the diurnal status of dipper, non-dipper, reverse-dipper, extreme-dipper was observed as presented in Figure 3.
The association between the non-dipper status and insulin resistance that was observed in the present study has already been demonstrated.\textsuperscript{21,24} Altered dipping status (non-dipping, reverse-dipping, extreme-dipping) have been shown in population-based studies to correlate with target organ damage, including cardiovascular morbidity and mortality\textsuperscript{25,28} progression of pre-existing renal disease\textsuperscript{29,30} and cerebrovascular disease.\textsuperscript{32} The small number of the patients included was a study limitation. Additional research is needed to identify the specific ways in which insulin resistance links the NAFLD and altered BP status.

**Conclusion**

The altered BP status of hypertension associated both a higher insulin resistance and a higher prevalence of NAFLD. This brings us to the conclusion that insulin resistance could be the pathogenic link between the NAFLD and altered BP status. Altered BP status could be a marker of the NAFLD in hypertensive patients.

**References**

8. Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein S. Insulin resistance in hypertension and...


ACKNOWLEDGEMENTS
No funding was obtained by pharmaceutical companies to carry out this study. None of the authors have any conflict of interest. All the authors were involved in the data collection and analysis.

PEER REVIEW
Not commissioned. Externally peer reviewed

CONFLICTS OF INTEREST
The authors declare that they have no competing interests

FUNDING
There was no source of funding

ETHICS COMMITTEE APPROVAL
The University Ethics Committee approved the study design